MorphoSys AG (MOR) Given a €77.00 Price Target by Independent Research GmbH Analysts
A number of other analysts also recently weighed in on the company. Commerzbank Ag set a €76.00 ($89.41) price target on MorphoSys AG and gave the stock a buy rating in a report on Monday, July 24th. Goldman Sachs Group, Inc. (The) set a €55.00 ($64.71) price target on MorphoSys AG and gave the stock a neutral rating in a report on Monday, July 24th. J P Morgan Chase & Co reiterated a neutral rating on shares of MorphoSys AG in a report on Monday, July 17th. HSBC Holdings plc set a €59.00 ($69.41) price target on MorphoSys AG and gave the stock a neutral rating in a report on Friday, July 14th. Finally, Berenberg Bank set a €68.00 ($80.00) price target on MorphoSys AG and gave the stock a buy rating in a report on Friday, July 14th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of €69.57 ($81.85).
Shares of MorphoSys AG (MOR) traded down 0.694% during midday trading on Monday, hitting €56.922. The company had a trading volume of 853 shares. The stock’s 50-day moving average price is €61.24 and its 200-day moving average price is €57.85. The stock’s market capitalization is €1.65 billion. MorphoSys AG has a one year low of €35.72 and a one year high of €70.90.
TRADEMARK VIOLATION WARNING: “MorphoSys AG (MOR) Given a €77.00 Price Target by Independent Research GmbH Analysts” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/08/19/morphosys-ag-mor-pt-set-at-77-00-by-independent-research-gmbh-updated-updated-updated.html.
MorphoSys AG Company Profile
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Stock Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related stocks with our FREE daily email newsletter.